Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review

DA Lane; S Raichand; D Moore; M Connock; A Fry-Smith; DA Fitzmaurice

doi:10.3310/hta17300

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review

DA Lane, S Raichand, D Moore, M Connock, A Fry-Smith, DA Fitzmaurice

Cardiovascular Sciences

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.

Original language	English
Pages (from-to)	1-188
Number of pages	188
Journal	Health Technology Assessment
Volume	17
Issue number	30
DOIs	https://doi.org/10.3310/hta17300
Publication status	Published - Jul 2013

Access to Document

10.3310/hta17300

Combined Anticoagulation and Antiplatelet Therapy for High-Risk Patients with Atrial Fibrillation: Systematic Review and Individual Patient Meta-Analysis
Lane, D., Fitzmaurice, D., Moore, D. & Lip, G.
NIHR EVALUATION, TRIALS AND STUDIES COORDINATING CENTRE
1/07/10 → 31/12/11
Project: Other Government Departments

Cite this

@article{a326203077674dec9e331502c68538f6,

title = "Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review",

abstract = "Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.",

author = "DA Lane and S Raichand and D Moore and M Connock and A Fry-Smith and DA Fitzmaurice",

year = "2013",

month = jul,

doi = "10.3310/hta17300",

language = "English",

volume = "17",

pages = "1--188",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "NIHR Health Technology Assessment Programme",

number = "30",

}

TY - JOUR

T1 - Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation

T2 - a systematic review

AU - Lane, DA

AU - Raichand, S

AU - Moore, D

AU - Connock, M

AU - Fry-Smith, A

AU - Fitzmaurice, DA

PY - 2013/7

Y1 - 2013/7

N2 - Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.

AB - Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.

U2 - 10.3310/hta17300

DO - 10.3310/hta17300

M3 - Article

C2 - 23880057

SN - 1366-5278

VL - 17

SP - 1

EP - 188

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 30

ER -

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review

Abstract

Access to Document

Fingerprint

Projects

Combined Anticoagulation and Antiplatelet Therapy for High-Risk Patients with Atrial Fibrillation: Systematic Review and Individual Patient Meta-Analysis

Cite this